Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 5Other hematologic neoplasm 2Myeloid 1

Conditions

Hematologic Neoplasms 10Multiple Myeloma 8Lymphoma 5Leukemia, Myeloid, Acute 5Neoplasms 4Glioma 3Thyroid Carcinoma, Anaplastic 2Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Neurofibromatosis 1 2Neoplasm Metastasis 2Myelodysplastic Syndromes 2Melanoma 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Leukemia 2Colorectal Neoplasms 2Breast Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Thrombocytosis 1Stomach Neoplasms 1Recurrence 1Rectal Neoplasms 1Primary Myelofibrosis 1

Interventions

trametinib 2fludarabine 2thymoglobulin 1omipalisib 1fludarabine phosphate 1Rituximab 1Melphalan 1Levetiracetam 1Injections 1Cytarabine 1Cyclophosphamide 1Busulfan 1Biopsy 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neurofibromatosis 1 × trametinib × Other hematologic neoplasm × Clear all
NCT03190915 2026-05-27

Trametinib in Treating Patients With Relapsed or Refractory Juvenile Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Active not recruiting
10 enrolled 11 charts
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

NCT05849662 2026-04-15

A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

Therapeutic Advances in Childhood Leukemia Consortium

Phase 1/2 Recruiting
58 enrolled
CNSOther hematologic neoplasm

Neurofibromatosis 1, Leukemia, Myelomonocytic, Juvenile

Data powered by HemOnc (CC BY 4.0) Colophon âš¡